PMA change mechanisms include panel-track supplements for significant design or performance changes or new indications requiring substantial clinical data; 180-day supplements for changes supported primarily by preclinical data, sometimes with confirmatory clinical data; real-time supplements for eligible minor changes; Special PMA Supplements, Changes Being Effected, for specified safety-enhancing changes; and 30-day notices for eligible manufacturing-method or process changes affecting safety or effectiveness. FDA may convert an inadequate 30-day notice to a 135-day supplement. Site-change supplements and changes reportable in periodic reports must also be considered. Panel-track does not mean an advisory panel meeting is always required.

Why it matters

Common pitfalls

•Evaluate eligibility for a 30-day notice rather than defaulting to a 180-day supplement; review time and conversion depend on the submission.
•Treating Special PMA Supplements (CBE) as universally applicable, they are restricted to specific change types defined in 21 CFR 814.39(d).
•Letting changes accumulate into an annual report when individually they crossed the supplement threshold.

Sources

21 CFR 814.39 - PMA Supplements · eCFR
Modifications to Devices Subject to PMA Guidance · FDA
IMDRF Documents · IMDRF
FDA supplement decision guidance · FDA
FDA supplements and amendments · FDA

Open full page

Select term B to compare.

Why compare MedTech terms side by side?

MedTech terminology is full of pairs that look interchangeable but carry very different regulatory, clinical, and commercial consequences. Picking the wrong framework, pathway, or standard early in a project can add months to a submission, invalidate clinical evidence, or trigger an audit finding. Side-by-side comparison is the fastest way to surface those differences before they become costly mistakes.

Each comparison on this page pulls from the same vendor-neutral, sourced definitions used throughout the MedTech Terms glossary. You see the one-line summary, the formal definition, why it matters in practice, common pitfalls, and the primary sources (FDA guidance, EU MDR/IVDR articles, ISO/IEC standards, MDCG documents, IMDRF principles) that back each entry. That makes the comparison defensible in regulatory strategy memos, design reviews, and submission narratives.

Common comparison patterns

Regulatory pathway choice - 510(k) vs PMA, 510(k) vs De Novo, Abbreviated vs Special 510(k).
Quality systems - QSR vs ISO 13485, QMSR vs QSR.
Software classification - SaMD vs SiMD, Locked vs adaptive AI.
EU frameworks - MDR vs IVDR, CE Mark vs UKCA.
Cybersecurity artifacts - SPDX vs CycloneDX SBOM, CVE vs CVSS.
Post-market actions - Recall vs field action, Removal vs correction.

How to use this tool

Pick term A and term B from the dropdowns, or click a preset above. The URL updates with both slugs so you can bookmark or share the exact comparison with a colleague, a notified body reviewer, or your regulatory consultant. Click Open full page on either side for the complete entry, including FAQs, related terms, and the full citation list. If you are not sure which term to start with, browse the Categories view or the A-Z index.

MedTech Terms is a vendor-neutral community resource sponsored by Blue Goat Cyber. Definitions are written for educational use and are not legal or regulatory advice.